July 23, 2024 12:18 PM EDTUpdated 02:54 PM
R&D
Pharma

Up­dat­ed: Mer­ck, with­out shar­ing de­tails, says RSV an­ti­body suc­cess­ful­ly pro­tect­ed in­fants

Max Bayer

Pharma Reporter

Mer­ck’s mon­o­clon­al an­ti­body to pro­tect in­fants from RSV hit its goals in a Phase 2b/3 tri­al, putting the US drug­mak­er a step clos­er to com­pet­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ex­clu­sive: In­flu­en­tial De­mo­c­rat will op­pose Biose­cure Act ahead of House vote

Astel­las CEO talks fu­ture be­yond Xtan­di as Japan­ese drug­mak­er puts roots in Boston

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

Lil­ly inks obe­si­ty deal with seed-stage RNA start­up as its ge­net­ic med­i­cines ef­fort en­ters the spot­light

sponsored

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

A service from the Financial Times